Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

Study ID
NCT00852228

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

OPTILIV

Trial Summary

The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetuximab and hepatic artery infusion of three-drug chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil).

More informations

Trial Starting Date

Jul 31,2008

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit